SGLT2 HYPE at a glance
Renown academic and non-academic partners
Envisaged recruiting sites
Countries all over Europe
Clinical Trials.gov Number:
NCT0680416
If you would like to learn more about the study plan and participation criteria click here.
Acronym
SGLT2 HYPE
Project title
SGLT2 inhibition for cardiovascular endpoint reduction in hypertension
Start Date
January 1st 2025
Project Duration
90 months
EU Contribution
€ 6 999 998.95
Grand Agreement Number
101156555
Coordinator
Universitätsklinikum
Schleswig-Holstein (UKSH) – Germany
Principal Investigator
Prof. Ingo Eitel
Coordinating Investigator
Dr. Elias Rawish
Clinical Project Management
Dr. Roza Saraei
Shaping the Future of Healthcare
Our Vision
To innovate hypertension treatment by introducing a new class of medication that improves heart and kidney health, ultimately reducing preventable illness, disability, and premature deaths on a global scale.
Our Mission
To lead pioneering research that establishes the effectiveness of SGLT2 inhibitors in hypertension management, influencing future treatment guidelines, improving patient outcomes, and driving transformative, life-saving advancements in healthcare.
The Trial
Implementation
The Team
The Trial
Analysis of protective benefits of Dapaglifozin
The SGLT2 HYPE trial is a large, international study evaluating the effects of dapagliflozin, an SGLT2 inhibitor, in elderly adults with uncontrolled hypertension at cardiovascular risk. This trial will monitor heart and kidney health outcomes in nearly 3,200 participants over a seven-year period, providing critical insights into the potential benefits of SGLT2 inhibitors for hypertension management.
Study Flowchart
At a glance
Implementation